Biotechnology

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

YANTAI, China, Jan. 26, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...

2022-01-26 10:52 4383

GenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- GenScript ProBio, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced onJanuary 26th, 2022 that it entered into a contract with InnoBation Bio to develop and manufacture clinical trial sample substances...

2022-01-26 09:00 3505

Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform

The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets,generation of novel molecules  non-existent in the chemical space, and prediction of outcomes for clini...

2022-01-25 13:23 2324

Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation (ADDF)

MONTREAL, Jan. 24, 2022 /PRNewswire/ -- Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an up toUS$2.1M investment from the Alzheimer's Drug Discovery Foundation (ADDF). The investment will be made throug...

2022-01-24 22:15 3547

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy

SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2022-01-24 15:22 5081

Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers

BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been a...

2022-01-24 13:10 3556

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, sele...

2022-01-23 18:35 4990

Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.

HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce thatBeijing MeiYan KongJian...

2022-01-21 11:12 6515

Successful Groundbreaking Ceremony for GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China

ZHENJIANG, China, Jan. 20, 2022 /PRNewswire/ -- GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has announced 2022 manufacturing expansion plans to meet the increasing demand for commercial cGMP plasmid and viral vector manufacturin...

2022-01-20 16:44 4875

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inIndonesia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3491

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the second consecutive year for the certification inAustralia & New Zealand * High scores in values, ethics and integrity serve as a driver ...

2022-01-20 08:00 2758

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

HYDERABAD, India, Jan. 19, 2022 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development & Manufacturing Organization  (CRO-CDMO), today announced the app...

2022-01-19 18:30 4111

Novotech Completes $255M Private Placement Transaction and $505M Refinancing to Accelerate Implementation of Growth Initiatives

SINGAPORE and SYDNEY, Jan. 19, 2022 /PRNewswire/ -- Novotech Health Holdings Pte. Ltd. ("Novotech Holdings" or the "Company") today announced the completion of a financing round ofUS$760 million (about 1.06 billion AUD) comprising a US$255 million private placement and a US$505 million refinancin...

2022-01-19 16:38 2713

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company r...

2022-01-19 09:00 9808

Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerat...

2022-01-18 20:00 2566

e-BEAUTY LAUNCHES DNA TEST KITS FOR ASIANS

* Singapore-Based Company Develops Direct-to-Consumer DNA Test For Asians * Asian Screening Array Technology (ASA) Provides Most Accurate DNA Results for Asians * Online-to-Offline (O2O) Platform Allows Consumers to Submit Saliva Samples From Home SINGAPORE, Jan. 18, 2022 /PRNewswire/ -- Sin...

2022-01-18 16:09 3106

Genetech Biotechnology Launches Four Exclusive Promo Bundles For Citrea In Celebration Of Chinese New Year

* Half the price deals for Prosperity Bundle, Pampering Duo, CNY (Clean New Year) Pair and Abundance Combo, for a limited time only SINGAPORE, Jan. 18, 2022 /PRNewswire/ -- Genetech Biotechnology, the exclusive distributor of Citrea, launches four exclusive promo bundles to celebrate Chinese Ne...

2022-01-18 15:16 2509

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity

HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing in its Phase2b clinica...

2022-01-18 08:00 3900

CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment

* Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in patients with metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) * A significant milestone in our pipeline development...

2022-01-18 08:00 5032

Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests

SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests toIsrael to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 mill...

2022-01-17 20:00 3167
1 ... 154155156157158159160 ... 185